Evidence map›Paper›PMID 38909116›Full record

ArticleAnnals of surgical oncology2024

Larger Tumor Size and Elevated Serum Chromogranin A Levels Predict Metastatic Disease on DOTATATE Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors.

Amanda Labora, Takayuki Shimizu, Alexandra Moore, Alykhan Premji, Wesley R Armstrong, Kevin Y Chen, Jason Link, Charlotte S Chan, Martin S Allen-Auerbach, Timothy R Donahue

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Amanda LaboraDepartment of Surgery, University of California, Los Angeles, CA, USA. alabora@mednet.ucla.edu.
Takayuki ShimizuDepartment of Surgery, University of California, Los Angeles, CA, USA.
Alexandra MooreDepartment of Surgery, University of California, Los Angeles, CA, USA.
Alykhan PremjiDepartment of Surgery, University of California, Los Angeles, CA, USA.
Wesley R ArmstrongDavid Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Kevin Y ChenDavid Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Jason LinkDepartment of Surgery, University of California, Los Angeles, CA, USA.
Charlotte S ChanDepartment of Surgery, University of California, Los Angeles, CA, USA.
Martin S Allen-AuerbachAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Timothy R DonahueDepartment of Surgery, University of California, Los Angeles, CA, USA.

Funding

Leveraging Vulnerabilities Induced by STING Activation in Pancreatic CancerR01CA250529 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DONAHUE, TIMOTHY R, RADU, CAIUS GABRIEL · 2021 to 2025
$3.1M
Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancerR01CA260678 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DONAHUE, TIMOTHY R, RADU, CAIUS GABRIEL · 2021 to 2025
$3.0M
NCI NIH HHS R01CA250529NIH HHS R01CA260678
6 · The paper itself

Abstract

purposeDOTATATE PET/CT (DOTATATE) is superior to conventional imaging in detecting metastasis for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, limited availability, high-cost, and additive radiation exposure necessitate guidelines for its use. This study seeks to investigate the relationship between clinical characteristics and metastasis on DOTATATE.

methodsThis was a retrospective analysis of 815 patients who underwent DOTATATE at UCLA from 2014 to 2022. After applying inclusion and exclusion criteria, the study cohort consisted of 163 patients with pathologically diagnosed GEP-NETs, who either underwent primary tumor resection within 1-year prior, or had not undergone resection at the time of DOTATATE imaging. The presence of metastasis was determined using DOTATATE. Fisher's exact test, chi-squared test, and Mann-Whitney test were conducted to compare intergroup difference. Multivariate analysis was performed to identify clinical characteristics associated with metastasis on DOTATATE.

resultsOf patients with GEP-NETs, 40.5% (n = 66) were diagnosed with metastases by using DOTATATE. Those with metastatic disease were more likely to exhibit a larger primary tumor size (median 3.4 vs. 1.2, cm, P < 0.001), elevated serum chromogranin A level (CgA, median 208 vs. 97, mg/ml, P = 0.005), and higher tumor grade (P < 0.001). Primary tumor size ≥2 cm and serum CgA level ≥150 ng/mL for metastatic disease had a sensitivity and specificity of 64% and 89%, and 72% and 59%, respectively. Multivariate analysis demonstrated that primary tumor size (≥2/<2, cm, odds ratio [OR] 47.90, P < 0.001), tumor functionality (functional/nonfunctional, adjusted OR 10.17 P = 0.008), serum CgA level (≥150/<150, ng/ml, OR 6.25, P = 0.005), and tumor grade G2 (G2/G1, OR 9.6, P < 0.001) were independently associated with metastases on DOTATATE.

conclusionsAmong patients with GEP-NETs, primary tumor size ≥2 cm, serum CgA level ≥150 ng/mL, and tumor grade G2 are associated with an increased risk of metastases on DOTATATE, and these predictors may be helpful to identify patients where DOTATATE is indicated for complete staging.

Indexed as

Chromogranin AIntestinal NeoplasmsNeuroendocrine TumorsPancreatic NeoplasmsStomach NeoplasmsAdultAgedBiomarkers, TumorFemaleFollow-Up StudiesHumansMaleMiddle AgedOrganometallic CompoundsPositron Emission Tomography Computed TomographyPrognosisBiomarkers, TumorChromogranin AOrganometallic CompoundsRadiopharmaceuticalsDOTATATENeuroendocrine tumorPancreasPET

Identifiers

PMID38909116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.